Overall survival by chemo‐/radiotherapy ‐ Chemotherapy only · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Perioperative chemotherapy leads to lower overall survival by chemo‐/radiotherapy ‐ Chemotherapy only compared with primary surgery (high certainty).
1 finding from 1 review
Overall survival among all patients · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Perioperative chemotherapy leads to lower overall survival among all patients compared with primary surgery (high certainty).
1 finding from 1 review
Presence of tumor‐free resection margin · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Perioperative chemotherapy showed no clear difference in presence of tumor‐free resection margin compared with primary surgery (moderate certainty).
1 finding from 1 review
Tumor stage at resection (T0 to T2 vs T3 to T4) · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Perioperative chemotherapy probably leads to higher tumor stage at resection (T0 to T2 vs T3 to T4) compared with primary surgery (moderate certainty).
1 finding from 1 review
Tumor stage at resection (N0 vs N+) · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Perioperative chemotherapy may leads to higher tumor stage at resection (N0 vs N+) compared with primary surgery (low certainty).
1 finding from 1 review
Postoperative morbidity RD · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
1 finding from 1 review
Postoperative mortality RD · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
1 finding from 1 review
Disease-free survival · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Perioperative chemotherapy showed no clear difference in disease‐free survival (landmark time 6 months) compared with primary surgery (high certainty).
1 finding from 1 review
Overall survival by type of data ‐ Individual patient data · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Perioperative chemotherapy leads to lower overall survival by type of data ‐ Individual patient data compared with primary surgery (high certainty).
1 finding from 1 review
Overall survival by type of data ‐ Aggregated data · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Perioperative chemotherapy probably leads to lower overall survival by type of data ‐ Aggregated data compared with primary surgery (moderate certainty).
1 finding from 1 review
Overall survival by tumor site ‐ Esophagus · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Perioperative chemotherapy showed no clear difference in overall survival by tumor site ‐ Esophagus compared with primary surgery (high certainty).
1 finding from 1 review
Overall survival by tumor site ‐ GE junction · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Perioperative chemotherapy leads to lower overall survival by tumor site ‐ GE junction compared with primary surgery (high certainty).
1 finding from 1 review
Overall survival by tumor site ‐ Stomach · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Perioperative chemotherapy showed no clear difference in overall survival by tumor site ‐ Stomach compared with primary surgery (high certainty).
1 finding from 1 review
Overall survival by chemo‐/radiotherapy ‐ Chemoradiotherapy · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Perioperative chemotherapy probably leads to lower overall survival by chemo‐/radiotherapy ‐ Chemoradiotherapy compared with primary surgery (moderate certainty).
1 finding from 1 review